Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone513-985-1920
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable
Aerpio Pharmaceuticals (NYSE:ARPO) Frequently Asked Questions
What is Aerpio Pharmaceuticals' stock symbol?
Aerpio Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARPO."
When is Aerpio Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Aerpio Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerpio Pharmaceuticals.
Has Aerpio Pharmaceuticals been receiving favorable news coverage?
Media coverage about ARPO stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aerpio Pharmaceuticals earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Aerpio Pharmaceuticals.
Who are some of Aerpio Pharmaceuticals' key competitors?
Some companies that are related to Aerpio Pharmaceuticals include Sirona Biochem (SBM), OncoCyte (OCX), OncoCyte (OCX), Botanix Pharmaceuticals (BOT), Circassia Pharmaceuticals (CIR), Orthocell (OCC), Ampio Pharmaceuticals (AMPE), Novoheart (NVH), Medlab Clinical (MDC), Medicure (MPH), 4d Pharma (DDDD), Pediapharm (PDP), IntelGenx Technologies (IGX), Equillium (EQ) and Bionomics (BNO).
What other stocks do shareholders of Aerpio Pharmaceuticals own?
Who are Aerpio Pharmaceuticals' key executives?
Aerpio Pharmaceuticals' management team includes the folowing people:
- Dr. Stephen J. Hoffman, CEO & Director (Age 65)
- Dr. Joseph H. Gardner, Founder, Pres & Director (Age 63)
- Mr. Michael W. Rogers, Chief Financial Officer (Age 59)
- Dr. Stephen Pakola, Chief Medical Officer (Age 50)
- Mr. Kevin G. Peters, Chief Scientific Officer (Age 62)
How do I buy shares of Aerpio Pharmaceuticals?
Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aerpio Pharmaceuticals' stock price today?
One share of ARPO stock can currently be purchased for approximately $0.56.
How big of a company is Aerpio Pharmaceuticals?
What is Aerpio Pharmaceuticals' official website?
How can I contact Aerpio Pharmaceuticals?
The company can be reached via phone at 513-985-1920.
MarketBeat Community Rating for Aerpio Pharmaceuticals (NYSE ARPO)
MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
